The field of probiosis has emerged as a new science with applications in farming and aqaculture as alternatives to antibiotics as well as prophylactics in humans. Probiotics are being developed commercially for both human use, primarily as novel foods or dietary supplements, and in animal feeds for the prevention of gastrointestinal infections, with extensive use in the poultry and aquaculture industries. The impending ban of antibiotics in animal feed, the current concern over the spread of antibiotic resistance genes, the failure to identify new antibiotics and the inherent problems with developing new vaccines make a compelling case for developing alternative prophylactics. Among the large number of probiotic products in use today are bacterial spore formers, mostly of the genus Bacillus. Used primarily in their spore form, these products have been shown to prevent gastrointestinal disorders and the diversity of species used and their applications are astonishing. Understanding the nature of this probiotic effect is complicated, not only because of the complexities of understanding the microbial interactions that occur within the gastrointestinal tract (GIT), but also because Bacillus species are considered allochthonous microorganisms. This review summarizes the commercial applications of Bacillus probiotics. A case will be made that many Bacillus species should not be considered allochthonous microorganisms but, instead, ones that have a bimodal life cycle of growth and sporulation in the environment as well as within the GIT. Specific mechanisms for how Bacillus species can inhibit gastrointestinal infections will be covered, including immunomodulation and the synthesis of antimicrobials. Finally, the safety and licensing issues that affect the use of Bacillus species for commercial development will be summarized, together with evidence showing the growing need to evaluate the safety of individual Bacillus strains as well as species on a case by case by basis.

The use of bacterial spore formers as probiotics

http://www.ssu.ac.ir/fileadmin/templates/fa/daneshkadaha/daneshkadah_pezeshki/goroha/rhienonogy/probiotics/artigo2.pdf

Probiotics in aquaculture: The need, principles and mechanisms of action and screening processes

Immunity enhancement in black tiger shrimp (Penaeus monodon) by a probiont bacterium (Bacillus S11)

http://www.raisaquaculture.net/uploads/media/aquaculture.pdf

The effect of Bacillus spp. bacteria used as probiotics on digestive enzyme activity, survival and growth in the Indian white shrimp Fenneropenaeus indicus

Effect of probiotics on growth performance and digestive enzyme activity of the shrimp Penaeus vannamei

Enhancement of disease resistance of kuruma shrimp, Penaeus japonicus, after oral administration of peptidoglycan derived from Bifidobacterium thermophilum

52歳女性. 突然の頭痛, 意識障害, 痙攣発作にて搬送となり諸検査にて左前大脳動脈遠位部動脈瘤破裂によるくも膜下出血と診断した. 再破裂防止目的の動脈瘤塞栓術に引き続きハイブリッド手術室にて神経内視鏡下脳内血腫除去術を施行し, 良好な転帰を得た. くも膜下出血急性期に脳室内血腫を神経内視鏡にて除去した報告はあるが, 本症例のようにコイル塞栓術に引き続き脳内血腫を神経内視鏡で治療し良好な結果を得た報告は少なく, 動脈瘤へのアクセス・血腫の局在と出血源近傍の血腫を残すなどの戦略により低侵襲な治療の1つになり得ると考えられる. 

Kazuo Tokushige

Papers

Enhancement of disease resistance of kuruma shrimp, Penaeus japonicus, after oral administration of peptidoglycan derived from Bifidobacterium thermophilum

A Case of Combination Treatment of Coil Embolization and Neuroendosopic Intracerebral Hematoma Removal in Ruptured Distal ACA Aneurysm in Hybrid OR